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ince the discovery by Kupfer and Foster
1 of a
link between depression and a shorter interval between
sleep onset and the first episode of rapid eye movement
sleep (REMS) than in controls,the relationship between
psychiatric disorders and sleep has been the focus of
intense research.Twenty years later,the results of a large
meta-analysis
2 could be summarized as follows.The sleep
of depressive patients is usually accompanied by several
anomalies when compared with controls: (i) increased
sleep onset latency;(ii) increased percentage of REMS;
(iii) increased REMS density;(iv) decreased sleep main-
tenance; (v) decreased percentage of slow-wave sleep
(SWS);and (vi) shortened REMS latency (RL).Although
the relative influences of age,gender,and severity of the
depressive episode on the observed sleep anomalies still
need to be fully clarified,it is relatively easy to distinguish
patients from controls on the basis of their sleep.
The above meta-analysis
2 also indicated that no sleep
anomaly unambiguously distinguishes depression from
other psychiatric symptoms,such as panic disorder,
3 gen-
eralized anxiety disorder,
4 obsessive-compulsive disor-
der,
5 schizophrenia,
6 severe dementia,
7 or borderline per-
sonality disorder.
8 Furthermore,no obvious distinction
between depression subclasses (primary, endogenous,
atypical,etc) has been demonstrated by elements of sleep
polysomnography.Perhaps the best supported distinction
is that between psychotic and nonpsychotic depression.
9
A few studies have tried the opposite route,ie,to cluster
psychiatric disorders or subtypes as a function of biolog-
ical markers,
10,11 but the results do not support qualitative
distinctions and mutually exclusive subtypes. Instead,
only quantitative differences emerged,favoring the con-
cept of a “depressive spectrum.”
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Several sleep anomalies are known to accompany depres-
sion and other psychiatric disorders, and to be partially
modified by drugs efficient on clinical symptoms. Many
puzzling theoretical questions remain, even after 30 years
of research, because these drugs do not act in a uniform
way: some reduce slow-wave sleep while others increase
it; some prolong rapid-eye movement sleep latency, while
others do not. The relationship between insomnia and
depression is likely to be a close one, since a large major-
ity of patients with depression suffer insomnia, and that
insomnia can predate depression by a few years. However,
questions remain here, too, since sleep deprivation is also
an effective means to combat depression, and some
patients present with hypersomnia rather than insomnia.
This review details the action of all current classes of anti-
depressants on sleep. It examines the predictive value of
baseline electronencephalographic sleep symptoms or
early modifications due to treatment for eventual clinical
efficiency. We will also discuss the two main theories on
the relationship between sleep and depression. The action
on sleep of all new drugs—and antidepressants in partic-
ular—is carefully examined during development, for
insomnia is currently considered to be a major health con-
cern in industrialized countries.    
© 2005, LLS SAS Dialogues Clin Neurosci. 2005;7:305-313.As a consequence, sleep anomalies and manipulations
are currently generally considered to be more useful for
uncovering neurophysiological mechanisms underlying
psychiatric disorders and symptoms and for understand-
ing sleep itself than as a diagnostic tool for clinicians.
Theories have been developed to explain what is
observed in the sleep of untreated patients with major
depressive disorder (MDD),the effects of drugs on their
sleep,and the effects of sleep manipulations,such as total
sleep deprivation or specific REMS deprivation.
Many interesting questions are still only partially
resolved.Do effective antidepressants counteract what
is observed in the sleep of untreated MDD patients?
Does this mean that whatever is counteracted reflected
depression in the first place? Is it through sleep modifi-
cation that drugs act on depression,or are the observa-
tions merely epiphenomena? Are there clues that a given
treatment will be effective in a fortnight? Are sleep
anomalies signs of a biological trait? Do they represent
the depressive state or do they go away after the clini-
cal episode is gone? Do they represent scars of previous
episodes? The situation for neuromediators is just as
complex.Serotonin (5-hydroxytryptamine [5-HT]),for
instance,is a target of choice in the fields of both depres-
sion and sleep disorders.Selective serotonergic agents are
available, which could help us clarify the relationships
between these two entities. However, the existence of
several receptor sites (5-HT1A-D,5-HT2A-C,5-HT3,and 
5-HT4), which have agonist or antagonist interactions
with each other,not to mention their potential interac-
tions with γ-aminobutyric acid (GABA),noradrenaline
(NA),or dopamine (DA) receptors,means that the map
to be built is likely to be a complicated one.
Sleep research is also now an important part of the devel-
opment of new psychotropic drugs,and almost every new
agent has its effects on sleep carefully analyzed.As these
data are the property of the patent owners and few are
published in peer-reviewed journals,it is not always pos-
sible to precisely evaluate how sleep studies actually
influence the future of these drugs,but it is likely to be
substantial.
Insomnia is probably the main reason why action on
sleep is studied so rigorously.Poor sleep has received an
increasing amount of attention in the last decade.
12,13
More than 90% of depressive patients experience insom-
nia,whereas only 5% to 8% experience hypersomnia.
14
Persistent insomnia multiplies the risk of developing
MDD within a year by three.
15 It increases the risk of
recurrence of depression.
16 Mood disorders are frequent,
but often go undiagnosed in chronic poor sleepers.
17
Optimal treatment of insomnia is thus currently a major
health concern in industrialized countries. Since drugs
can alleviate or worsen sleep initiation and maintenance,
the development and selection of antidepressants in
patients should take insomnia into account.Also,anti-
depressants may exacerbate restless legs or periodic limb
movement syndromes, which results in a worsening of
insomnia.
In this review,we will (i) describe the effects of the main
antidepressants on sleep; (ii) examine which signs are
predictive of good prognosis;and (iii) analyze the theo-
retical aspects of sleep anomalies in depression and
actions on sleep by antidepressants.
Effects of antidepressant drugs on sleep
Monoamine oxidase inhibitors 
Phenelzine,a monoamine oxidase inhibitor (MAOI),can
almost completely suppress REMS after a few weeks of
treatment,
18 both in healthy controls (HCs) and MDD
patients.This is also the case with other MAOIs,such as
nialamide,pargyline,and mebanazine.This suppression
coincides with the beginning of the antidepressant effect,
which suggests that a physiological link exists between
REMS suppression and antidepressant effect. In most
cases,the influence of MAOIs on SWS is not very pro-
nounced, although they are usually considered to
decrease sleep efficiency.
19
Moclobemide,a reversible MAOI,has shown contradic-
tory results,with one study showing it to be associated
with better sleep efficiency and enhanced REMS with
shorter RL in MDD patients,
20 and one study showing
almost the opposite.
21
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Selected abbreviations and acronyms
MAOI monoamine oxidase inhibitor
MDD major depressive disorder
NaSSA noradrenergic and specific serotonergic 
antidepressant
REMS rapid eye movement sleep
RL rapid eye movement sleep latency
SNRI serotonin and norepinephrine reuptake inhibitor
SSRI selective serotonin reuptake inhibitor
SWS slow-wave sleep
TCA tricyclic antidepressantTricyclic antidepressants
The REMS-suppressing potencies of the tricyclic antide-
pressants (TCAs) are different from those of the MAOIs,
as REMS can be suppressed almost immediately.
Clomipramine, for instance, produces a profound sup-
pression of REMS
22,23 in HCs. Imipramine
24 and
desipramine
25 have also shown profound REMS-sup-
pressing effects,at least in HCs and animals.The influence
of TCAs on REMS appears to be less sustained than with
MAOIs,as longitudinal studies show normal to increased
levels of REMS.
26 Doxepin was also found to have REMS-
suppressing effects.
22Amitryptiline was found to reduce
REMS in a group of depressed subjects.
27 A REMS
rebound is usually observed on withdrawal.
Interestingly, not all TCAs have REMS-suppressing
effects.For instance,trimipramine,
28 iprindole,
29 and vilox-
azine
30 have no significant effect on REMS.
As a group, TCAs tend to increase SWS, except for
clomipramine.
31 One study on clomipramine in a group
of MDD patients using spectral analysis has shown a sig-
nificant increase in the delta bands, corresponding to
SWS.Desipramine was associated with sleep-onset diffi-
culty in a group of MDD patients.
32
Tetracyclics
Mianserin has been shown to reduce REMS in rats.
33 It
does not change REMS duration in HCs
34 and MDD
patients.
35 Maprotiline reduces REMS and increases
stage 2 sleep in HCs.
36These compounds tend to increase
SWS.
33
Selective serotonin reuptake inhibitors
The selective serotonin reuptake inhibitor (SSRI) flu-
voxamine was found to suppress REMS and prolong the
RL in a group of MDD patients,but had no significant
action on SWS or delta band in spectral analysis.
32
Paroxetine was shown to reduce total sleep time and
sleep efficiency in MDD patients,
37,38 while REMS
decreased and RL increased.
In MDD patients,fluoxetine was associated with more
awakenings,decreased sleep efficiency,decreased SWS,
and decreased sleep efficiency. RL is prolonged and
REMS is reduced.
39-41 Treatment of MDD patients
showed sertraline to prolong sleep latency and decrease
REMS time.
42
Citalopram was shown to suppress REMS in a sustained
manner and to be accompanied by REMS rebound at
withdrawal.
43 No change was observed in the delta band
upon spectral analysis.
Trazodone (100 to 150 mg/day) was found to reduce
REMS and increase SWS,as well as subjective estimations
of sleep quality in a group of middle-aged patients with
insomnia.
44 Mouret et al
45 found total sleep time and SWS
to be increased with 400 to 600 mg/day of trazodone in a
group of MDD patients,whereas REMS and RL were not
significantly modified.In another study using lower doses,
Van Bemmel et al
46 found no changes in SWS.
Nefazodone was shown to reduce the number of awak-
enings and improve sleep efficiency,and also stabilize,
40
or even increase,
47 REMS time in HCs and MDD
patients.SWS was reduced.SSRIs have been shown to
exacerbate periodic limb movement syndrome.
48
Serotonin and norepinephrine reuptake inhibitors
The serotonin and norepinephrine reuptake inhibitor
(SNRI) venlafaxine was found to increase wake time and
sleep stages 1,2,and 3 in HCs.REMS was strongly sup-
pressed and RL was prolonged.
47,49
Noradrenergic and specific serotonergic antidepressant
The noradrenergic and specific serotonergic antidepres-
sant (NaSSA) mirtazapine was shown to promote sleep
in HCs. It shortened sleep onset and deep sleep was
increased. RL was increased; nighttime wakening was
reduced.
50 In MDD patients, sleep efficiency and total
sleep time were increased.REMS was not affected.
51
Other antidepressants
Tianeptine was not shown to suppress REMS in a signif-
icant way in HCs
52,53 or patients with comorbid depression
and alcoholism.
54 Moreover,a study in young HCs found
no effect on EEG sleep parameters at therapeutic
dosages (37.5 mg/day).
55The same study found improve-
ment in sleep with tianeptine using the subjective Leeds
sleep evaluation questionnaire.
Summary of effects of common antidepressants on sleep
Table I summarizes the main results cited above.The
large majority of antidepressant drugs suppress or elim-
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and NaSSAs) or after about 2 weeks of treatment
(MAOIs).There are,however,a few notable exceptions
(trimipramine, iprindole, tianeptine, viloxazine, nefa-
zodone).Deep sleep can be either increased (trazodone,
nefazodone, mirtazapine), not modified (most MAOIs,
fluvoxamine),or decreased (clomipramine,desipramine,
phenelzine, fluoxetine, paroxetine, sertraline, venlafax-
ine).The effects after long-term treatment are not well
documented,but tend to show a reduction of the initial
impact.There are few differences as a whole between
the effects of pharmacological substances on HCs and
patients. Spectral analysis in the delta band has gener-
ally confirmed what is observed for visually analyzed
deep sleep.As we can see, antidepressants generally do
have effects on sleep, although these vary in direction
and intensity from drug to drug.These actions are due
to the neuromediators targeted to combat depression,
and which also act on sleep.The various receptor pro-
files on which they exert their action explain these dif-
ferences.
Prediction of treatment efficacy
Polysomnographic measurements for predicting future
efficacy
Because a delay of at least 2 weeks exists between the first
intake of an antidepressant drug and its clinical action in
relieving symptoms,the matching of the right antidepres-
sant to a given patient can be quite a challenge. Drug
dosage modifications do not yield immediate results
either,and switches between compounds include periods
of overlap, which may prove uncomfortable for the
patient.In this context,any markers predicting the efficacy
of a substance from baseline characteristics or very soon
after treatment initiation (pharmacological,psychothera-
peutic,or sleep changes) could make optimal treatment
selection a faster and smoother process.Several predictors
of future efficiency have been evidenced.
• Pretreatment (baseline) short RL has been linked to
positive response.
56
• Pretreatment all-night electroencephalographic (EEG)
spectral analysis has also been shown to predict clini-
cal response.Higher delta band and lower alpha,beta,
and theta band power were found in future respon-
ders.
57 This, however, was not confirmed in another
study in MDD patients.
58
• Pretreatment higher levels of REMS density predicted
poor prognosis.
Initial REMS suppression by the substance has been
tested for its prognostic value.Kupfer et al
59,60 and Gillin
et al
61 have shown that REMS suppression in the initial
two nights of TCA treatment was predictive of thera-
peutic efficacy. Höchli et al
62 have shown similar results
for clomipramine.This finding has not been confirmed
with SSRIs. Although promising, these strategies are
actually seldom used in practice.
Specific antidepressants for specific depression 
subtypes?
Just as the search for sleep correlates of the different
subtypes of depression has generally been elusive, the
demonstration that it is more efficient to target specific
neuroreceptors as a function of the clinical characteris-
tics of a patient (ie, more serotonergic, more noradren-
ergic,and more dopaminergic treatments) has not been
very conclusive so far.This is likely to be due to the com-
plexity and uncovered interactions between neurome-
diators and receptors.
32
Theories
Several arguments support the hypothesis that sleep dys-
regulation is closely linked to the underlying patho-
physiology of depressive disorders: (i) patients suffer
from either insomnia or hypersomnia in almost all cases;
(ii) patients with chronic insomnia alone are at risk for
developing depression or suffering a recurrence of
depression; (iii) pharmacological agents active on
depression modify sleep, usually counteracting what is
observed in these patients at baseline; and (iv) sleep
deprivation is an efficient way to relieve depression
symptoms in 50% of the patients,although this effect is
only transient. Two main theories have attempted to
explain what is observed.
S-deficiency
If depression is characterized by insomnia, does the
restoration of sleep continuity and intensity parallel or
predict clinical recovery? One of the hypotheses of
depression is that the first step lies in a weakening of
SWS or spectral delta band power,which in turn allows
for REMS to use the lost ground and appear sooner in
Basic research
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Table I. Main effects of antidepressants on sleep. NS, not significant; HC, healthy control; MDD, major depressive disorder; REMS, rapid eye move-
ment sleep; RL, REMS latency; SWS, slow-wave sleep;  (+), slightly positive effect; +, positive effect; ++, marked positive effect; (-), slightly
negative effect; -, negative effect; --, marked negative effect; MAOI, monoamine oxidase inhibitor; SSRI, selective serotonin reuptake inhibitor;
NARI, noradrenaline reuptake inhibitor; SNRI, serotonin and norepinephrine reuptake inhibitor; NaSSA, noradrenergic and specific serotonin
reuptake antidepressant.
HCs/MDD REMS RL SWS Effect REMS RL SWS Effect REMS
(acute) (acute) (acute) (acute) (>21 days) (>21 days) (>21 days) (>21 days) (rebound on
withdrawal)
• MAOIs
Phenelzine HC - NS
MDD NS NS NS -- +++ +
Moclobemide HC - NS NS -
MDD (-) + NS NS + NS +
• TCAs
Clomipramine HC -- ++ - - -- - +
MDD -- +++ - - - ++ -
Amitriptyline HC - ++ + + -- + NS +
MDD - ++ ++ NS - ++ + +
Trimipramine HC NS + NS + + NS
MDD NS + + NS NS +
Mianserin HC - + + +
MDD (-) + NS + - + +
Trazodone HC - + + NS +
MDD NS NS + NS NS +
Nefazodone HC + NS NS NS + NS NS
MDD NS - - + NS - +
• SSRIs
Fluoxetine HC - + - - - ++ - +
MDD NS NS - NS (-) + - NS
Citalopram HC -- ++ NS - - ++ - +
MDD -- ++ - - + NS +
Fluvoxamine HC -- ++ NS - - ++ - +
MDD -- ++ - - - + NS +
Sertraline HC -- ++ NS - - ++ - +
MDD -- ++ - - + NS +
Paroxetine HC -- ++ NS - - ++ - +
MDD -- ++ - - - + - NS +
• NARIs
Reboxetine HC
MDD NS NS - - + -
• SNRIs
Venlafaxine HC -- ++ -
MDD
• NaSSAs
Mirtazapine HC NS + + +
MDD NS NS + NS + +
• Other antidepressants
Tianeptine HC + - + NS NS +
MDD + - NS +the night, with increased REMS and shorter REMS
latency.
63This hypothesis is itself derived from Borbély’s
general model of sleep regulation,
64 where process “S”
represents EEG sleep delta bands corresponding to
deep sleep (roughly corresponding to stages 3 and 4 on
visually analyzed hypnograms). One of the ways to test
this hypothesis was to measure the sleep EEG spectral
power response to antidepressants.A study using spec-
tral analysis and comparison of the effects of trazodone
and citalopram in a group of MDD patients was per-
formed to measure whether a parallel could be drawn
between potential modifications and timing of clinical
recovery.The study found that the delta band did not
show significant modifications during the 5 weeks of
treatment and the timing for changes in other bands did
not correlate with clinical changes.
65 Furthermore, anti-
depressants vary considerably in their actions on sleep
continuity, from deterioration to improvement, so that
the role of non-REMS restoration remains elusive.
Excessive REMS pressure
Vogel et al
66 have reviewed 251 studies focusing on the
influence of a variety of drugs (barbiturates, benzodi-
azepines,antidepressants,antipsychotics,lithium,opioids,
amine precursors, and ethanol) on REMS in animals,
human HCs, and patients with MDD.Their conclusion
was that all drugs that produce large and sustained
decrements of REMS time and were followed by a
REMS rebound upon withdrawal are active on endoge-
nous depression.Treatment by antidepressant drugs—
and also by (partial, REMS-specific; or full) sleep 
deprivation, electronconvulsive treatment, or psy-
chotherapy—would parallel or act through the reversal
of the abnormal characteristics observed in the sleep of
depressed patients.Whatever the underlying mechanism,
RL is shortened during depression and should be pro-
longed; REMS percentage is higher during depression
and should be reduced.
It appears, however, that the general rule of REMS-
reducing, RL-lengthening efficient antidepressants suf-
fers many exceptions,because several efficient drugs do
not reduce REMS (Table I).Therefore,either more than
one mechanism is at work and only a fraction of the
antidepressants comply with the rule,or sleep modifica-
tions during treatment are only indirectly linked to effi-
ciency against depression. Furthermore, the degree to
which REMS is suppressed and the time where the sup-
pression occurs do not in general correspond to clinical
improvement (except for MAOIs).
Summary of theories
Although sleep and the neurophysiological mechanisms
that determine it are likely to be very close to the mech-
anisms that define depression, they are most probably
not identical and we certainly cannot claim that sleep
ought to be corrected (REMS reduced,RL prolonged,
SWS/delta sleep increased,better continuity) in order for
depression to be relieved. Sleep is not a mere epiphe-
nomenon, as testified by the frequent association with
insomnia, the efficiency of sleep manipulations on
depression, and the modifications induced by antide-
pressant drugs,but it is probably not a necessary compo-
nent of the mechanisms of depression.
Conclusions
More than 30 years of sleep research in the domain of
depression and other psychiatric disorders have yielded
many interesting results.On the other hand,several dead-
end alleys have been explored,following promising con-
cepts and generating some frustration.We are still missing
a global and comprehensive theory to explain what is
observed,both at baseline and after some time of treat-
ment.This should be considered in the context of the huge
complexity of the issues.To start with, the functions of
sleep itself are still very poorly understood (see reference
67 for a recent overview on the issue),so that we hardly
can tell how much sleep or what kind of sleep is recom-
mended for a given person. The distinction between
REMS and non-REMS implies another level of complex-
ity that is not yet resolved. Depression is currently
regarded as part of a spectrum of disorders,ranging from
anxiety to psychosis.Neuromediators are numerous and
can be both agonists or antagonists of each other,which
results in major difficulties in determining what does what.
It is therefore no surprise that no simple and easy answer
to these complex issues is yet at hand.More insight and
more research are definitely needed.
One domain where sleep research is already useful today
is insomnia, for it may predate, accompany, or worsen
depression.The finding of new antidepressant drugs that
will also take good care of insomnia without prompting
daytime sleepiness will undoubtedly increase compliance
and prognosis. ❏
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Contribución de la investigación 
del sueño al desarrollo de nuevos 
antidepresivos
Se sabe que algunas anomalías del sueño acompa-
ñan a la depresión y a otros trastornos psiquiátri-
cos, y pueden ser parcialmente modificadas por fár-
macos eficaces sobre síntomas clínicos. A pesar de
30 años de investigación, aun muchas preguntas
teóricas siguen constituyendo un enigma ya que
estos fármacos no actúan de una manera uniforme:
algunos reducen el sueño de ondas lentas mientras
que otros lo aumentan; algunos prolongan la laten-
cia del sueño de movimientos oculares rápidos y
otros no. La relación entre insomnio y depresión es
probable que sea estrecha ya que la mayor parte de
los pacientes con depresión padece insomnio, y el
insomnio puede anteceder a la depresión en algu-
nos años. Sin embargo, hay otras preguntas que
persisten ya que la privación de sueño constituye
un recurso eficaz para combatir la depresión y algu-
nos pacientes presentan hipersomnia más que
insomnio. Esta revisión detalla la acción de todos
los antidepresivos actuales sobre el sueño. Se exa-
mina el valor predictor de síntomas del electroen-
cefalograma de sueño basal o modificaciones pre-
coces debidas al tratamiento para determinar la
eventual eficacia clínica del fármaco. También se
discuten las dos principales teorías acerca de la rela-
ción entre sueño y depresión. Los efectos sobre el
sueño de todos los nuevos fármacos y en particular
de los antidepresivos son examinados cuidadosa-
mente durante el proceso de desarrollo de éstos ya
que se considera que el insomnio actualmente cons-
tituye un gran problema de salud en los países
industrializados.
Contribution de la recherche sur le sommeil
au développement de nouveaux antidépres-
seurs
De nombreuses anomalies du sommeil accompa-
gnent la dépression ainsi que d'autres troubles psy-
chiatriques et sont partiellement modifiées par les
substances efficaces sur les symptômes cliniques.
Plusieurs questions théoriques troublantes persis-
tent après 30 années de recherche, puisque ces sub-
stances n'agissent pas de façon uniforme : certaines
réduisent le sommeil profond à ondes lentes alors
que d'autres l'accroissent ; certaines prolongent la
latence d'apparition du sommeil paradoxal alors
que d'autres, non. Les liens entre insomnie et
dépression sont vraisemblablement étroits puis-
qu'une grande majorité des patients présentant
une dépression sont insomniaques et que l'insom-
nie anticipe parfois la dépression de plusieurs
années. Des questions restent posées ici aussi,
puisque la privation de sommeil est aussi un traite-
ment efficace de la dépression, et que certains
patients sont hypersomniaques au lieu de dormir
trop peu. La revue présentée ici détaille l'action de
toutes les classes connues d'antidépresseurs sur le
sommeil et examine la valeur prédictive sur l'effi-
cacité clinique à venir de symptômes EEG (élec-
troencéphalogramme) de départ ou de modifica-
tions précoces par le traitement ; les deux théories
principales touchant aux relations entre sommeil et
dépression sont débattues. L'action sur le sommeil
de nouvelles substances, et des antidépresseurs en
particulier, est examinée en détail pendant leur
développement, du fait que l'insomnie est consi-
dérée actuellement comme un problème de santé
majeur dans les pays industrialisés.
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